Skip to content
20-F

Annual Report (Foreign)

Addex Therapeutics Ltd. ADXN

0001104659-25-049380

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2024 98.11M sh
Shares Diluted FY 2024 · Dec 31, 2023 74.31M sh
Shares Diluted FY 2024 · Dec 31, 2022 45.18M sh
Shares Outstanding FY 2024 · Dec 31, 2024 128.29M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −5.37M
Operating Cash Flow FY 2024 · Dec 31, 2023 −7.99M
Operating Cash Flow FY 2024 · Dec 31, 2022 −16.44M
Cash And Equivalents FY 2024 · Dec 31, 2024 3.34M
Cash And Equivalents FY 2024 · Dec 31, 2023 3.87M
Cash And Equivalents FY 2024 · Dec 31, 2022 6.96M
Cash And Equivalents FY 2024 · Dec 31, 2021 20.48M
Stockholders Equity FY 2024 · Dec 31, 2024 9.68M
Stockholders Equity FY 2024 · Dec 31, 2023 1.15M
Stockholders Equity FY 2024 · Dec 31, 2022 4.91M
Stockholders Equity FY 2024 · Dec 31, 2021 16.93M
Current Liabilities FY 2024 · Dec 31, 2024 802.09K
Current Liabilities FY 2024 · Dec 31, 2023 2.89M
Current Assets FY 2024 · Dec 31, 2024 3.54M
Current Assets FY 2024 · Dec 31, 2023 4.23M
Total Assets FY 2024 · Dec 31, 2024 10.68M
Total Assets FY 2024 · Dec 31, 2023 4.64M
Eps Diluted FY 2024 · Dec 31, 2024 0.07
Eps Diluted FY 2024 · Dec 31, 2023 −0.14
Eps Diluted FY 2024 · Dec 31, 2022 −0.46
Eps Basic FY 2024 · Dec 31, 2024 0.07
Eps Basic FY 2024 · Dec 31, 2023 −0.14
Eps Basic FY 2024 · Dec 31, 2022 −0.46
Rd Expense FY 2024 · Dec 31, 2024 854.31K
Rd Expense restated FY 2024 · Dec 31, 2023 1.19M
Rd Expense restated FY 2024 · Dec 31, 2022 8.24M
Net Income FY 2024 · Dec 31, 2024 7.06M
Net Income FY 2024 · Dec 31, 2023 −10.56M
Net Income FY 2024 · Dec 31, 2022 −20.8M
Operating Income FY 2024 · Dec 31, 2024 −2.76M
Operating Income restated FY 2024 · Dec 31, 2023 −2.24M
Operating Income restated FY 2024 · Dec 31, 2022 −10.54M